Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1977 1
1998 1
2000 3
2003 3
2004 3
2005 3
2006 2
2007 3
2008 1
2009 3
2010 3
2011 4
2012 4
2013 7
2014 7
2015 1
2016 3
2017 6
2018 6
2019 12
2020 8
2021 7
2022 8
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Among authors: hebert v. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.
Rituximab in pemphigus.
Hebert V, Joly P. Hebert V, et al. Immunotherapy. 2018 Jan;10(1):27-37. doi: 10.2217/imt-2017-0104. Epub 2017 Oct 24. Immunotherapy. 2018. PMID: 29064314
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: hebert v. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
Hébert V, Boulard C, Houivet E, Duvert Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, Didona B, Marinovic B, Schmidt E, Schumacher N, Hünefeld C, Schanz S, Kern JS, Hofmann S, Bouyeure AC, Picard-Dahan C, Prost-Squarcioni C, Caux F, Alexandre M, Ingen-Housz-Oro S, Bagot M, Tancrede-Bohin E, Bouaziz JD, Franck N, Vabres P, Labeille B, Richard MA, Delaporte E, Dupuy A, D'Incan M, Quereux G, Skowro F, Paul C, Livideanu CB, Beylot-Barry M, Doutre MS, Avenel-Audran M, Bedane C, Bernard P, Machet L, Maillard H, Jullien D, Debarbieux S, Sassolas B, Misery L, Abasq C, Dereure O, Lagoutte P, Ferranti V, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; French Study Group on Autoimmune Bullous Skin Diseases; Autoimmune Bullous Skin Disease Task Force of the European Academy of Dermatology and Venereology. Hébert V, et al. J Invest Dermatol. 2019 Jan;139(1):31-37. doi: 10.1016/j.jid.2018.04.042. Epub 2018 Oct 6. J Invest Dermatol. 2019. PMID: 30301637 Free article. Review.
Oral delivery of xenon for cardiovascular protection.
Yin X, Moody MR, Hebert V, Klegerman ME, Geng YJ, Dugas TR, McPherson DD, Kim H, Huang SL. Yin X, et al. Among authors: hebert v. Sci Rep. 2019 Oct 1;9(1):14035. doi: 10.1038/s41598-019-50515-3. Sci Rep. 2019. PMID: 31575906 Free PMC article.
DRESS with eslicarbazepine: The value of allergological exploration.
Tejedor I, Assier H, Morice C, Bauvin O, Carvalho P, Hébert V, Gautier C, Hervouet C, Joly P, Tétart F. Tejedor I, et al. Among authors: hebert v. Ann Dermatol Venereol. 2021 Sep;148(3):187-190. doi: 10.1016/j.annder.2020.10.019. Epub 2021 Feb 10. Ann Dermatol Venereol. 2021. PMID: 33581860 No abstract available.
Agranulocytosis-complicated DRESS with medullar HHV-6 replication.
Lehericey M, Tétart F, Carvalho P, Bauvin O, Hervouet C, Joly P, Hébert V. Lehericey M, et al. Among authors: hebert v. Clin Case Rep. 2020 Jun 26;8(10):1928-1931. doi: 10.1002/ccr3.3033. eCollection 2020 Oct. Clin Case Rep. 2020. PMID: 33088521 Free PMC article.
IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.
Font G, Walet-Balieu ML, Petit M, Burel C, Maho-Vaillant M, Hébert V, Chan P, Fréret M, Boyer O, Joly P, Calbo S, Bardor M, Golinski ML. Font G, et al. Among authors: hebert v. Biomedicines. 2022 Jul 22;10(8):1774. doi: 10.3390/biomedicines10081774. Biomedicines. 2022. PMID: 35892674 Free PMC article.
Linear IgA bullous dermatosis treated with rituximab.
Pinard C, Hebert V, Lecuyer M, Sacre L, Joly P. Pinard C, et al. Among authors: hebert v. JAAD Case Rep. 2019 Jan 12;5(2):124-126. doi: 10.1016/j.jdcr.2018.11.004. eCollection 2019 Feb. JAAD Case Rep. 2019. PMID: 30671527 Free PMC article. No abstract available.
89 results